Literature DB >> 15894933

Expression of urokinase-type plasminogen activator receptor (uPAR) in primary central nervous system neoplasms.

Mohammad Salajegheh1, Anna Rudnicki, Thomas W Smith.   

Abstract

The cellular receptor for urokinase-type plasminogen activator receptor (uPAR) is a member of the glycosylphosphatidylinositol (GPI) anchored protein family. It is a specific cell surface receptor for its ligand, urokinase-type plasminogen activator, which catalyzes the formation of plasmin from plasminogen to generate the proteolytic cascade and leads to the breakdown of the extracellular matrix. uPAR has been shown to correlate with a propensity to tumor invasion and metastasis in several types of non-central nervous system tumors. In this study, the authors examined the immunohistochemical expression of uPAR in 65 primary brain tumors (5 pilocytic astrocytomas, 5 diffuse astrocytomas, 6 anaplastic astrocytomas, 8 glioblastomas, 5 oligodendrogliomas, 4 oligoastrocytomas, 6 anaplastic oligoastrocytomas, 4 gangliogliomas, 4 ependymomas, 5 medulloblastomas, 6 schwannomas, 5 meningiomas, 2 atypical meningiomas). The specimens were evaluated for intensity of immunostaining (0-3 scale), cellular localization of staining, and specific or unique patterns of staining. Some degree of uPAR expression was observed in all tumors. A significant positive correlation (P = 0.0006) between tumor grade and staining intensity was identified within the astrocytoma/glioblastoma subgroup, suggesting a possible correlation with anaplastic change and propensity to tumor invasion. Expression of uPAR in nonmalignant, noninvasive tumors such as schwannoma and meningioma suggests that uPAR may have other biologic functions in addition to promotion of tumor invasion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15894933     DOI: 10.1097/01.pai.0000138448.85231.da

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  8 in total

Review 1.  Caveolin-1, caveolae, and glioblastoma.

Authors:  Marie-Odile Parat; Gregory J Riggins
Journal:  Neuro Oncol       Date:  2012-04-16       Impact factor: 12.300

2.  A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma.

Authors:  Jill Wykosky; Jingjing Hu; German G Gomez; Tiffany Taylor; Genaro R Villa; Donald Pizzo; Scott R VandenBerg; Amy Haseley Thorne; Clark C Chen; Paul S Mischel; Steven L Gonias; Webster K Cavenee; Frank B Furnari
Journal:  Cancer Res       Date:  2014-11-28       Impact factor: 12.701

3.  Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.

Authors:  Jingjing Hu; Minji Jo; Webster K Cavenee; Frank Furnari; Scott R VandenBerg; Steven L Gonias
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-06       Impact factor: 11.205

4.  Tumor-associated soluble uPAR-directed endothelial cell motility and tumor angiogenesis.

Authors:  J S Rao; M Gujrati; C Chetty
Journal:  Oncogenesis       Date:  2013-06-24       Impact factor: 7.485

Review 5.  EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment.

Authors:  Stefanie Keller; Mirko H H Schmidt
Journal:  Int J Mol Sci       Date:  2017-06-18       Impact factor: 5.923

6.  The Urokinase Receptor Induces a Mesenchymal Gene Expression Signature in Glioblastoma Cells and Promotes Tumor Cell Survival in Neurospheres.

Authors:  Andrew S Gilder; Letizia Natali; Danielle M Van Dyk; Cristina Zalfa; Michael A Banki; Donald P Pizzo; Huawei Wang; Richard L Klemke; Elisabetta Mantuano; Steven L Gonias
Journal:  Sci Rep       Date:  2018-02-14       Impact factor: 4.379

7.  Identification of a novel role of IL-13Rα2 in human Glioblastoma multiforme: interleukin-13 mediates signal transduction through AP-1 pathway.

Authors:  Rukmini Bhardwaj; Akiko Suzuki; Pamela Leland; Bharat H Joshi; Raj K Puri
Journal:  J Transl Med       Date:  2018-12-20       Impact factor: 5.531

8.  uPAR promotes formation of the p130Cas-Crk complex to activate Rac through DOCK180.

Authors:  Harvey W Smith; Pierfrancesco Marra; Christopher J Marshall
Journal:  J Cell Biol       Date:  2008-08-25       Impact factor: 10.539

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.